Investors of Altimmune, Inc. Facing Claims of Fraud Under Investigation by Pomerantz Law Firm
On July 12, 2025, the prestigious Pomerantz Law Firm announced that it is initiating an investigation into potential claims on behalf of investors who hold shares in Altimmune, Inc., a biopharmaceutical company trading under the NASDAQ symbol ALT. Investors who may have suffered financial losses due to recent events are being encouraged to contact the firm, demonstrating the seriousness of the allegations surrounding the company.
The basis for this inquiry stems from allegations that Altimmune, along with its executive leaders, may have been involved in securities fraud or engaged in other unlawful business practices. Recently, on June 26, 2025, Altimmune released a press statement summarizing the results of the IMPACT Phase 2b trial, which focused on a drug called pemvidutide aimed at treating metabolic dysfunction-associated steatohepatitis (MASH). While the company labeled the results as "positive," an in-depth analysis was less optimistic regarding key endpoints. Specifically, the reported effectiveness of fibrosis improvement was 31.8% and 34.5% for pemvidutide administered at doses of 1.2 mg and 1.8 mg, respectively, contrasted with a 25.9% improvement in the placebo group. Alarmingly, these differences were not found to be statistically significant.
This critical information had an immediate and dramatic impact on Altimmune's stock market performance. Following the press release, shares of the company plummeted, with a staggering drop of $4.10, equating to a 53.18% decline, leading to a closing price of just $3.61 per share on that day. Such a drastic decline raises red flags, prompting Pomerantz to step in on behalf of the investors who might have been misled regarding the efficacy and safety of Altimmune's treatments.
Pomerantz Law Firm, known for its exemplary work in corporate law and class actions, highlights the importance of transparency in the life sciences sector, especially when it comes to claims made about medical treatments. Founded over 85 years ago by Abraham L. Pomerantz, a pioneer in class action lawsuits, the firm prides itself on advocating for shareholders’ rights. It is recognized for recovering substantial damages for those who have faced corporate wrongdoing, and its current investigation into Altimmune exemplifies its ongoing commitment to this mission.
Investors affected by these developments are urged to act swiftly. Pomerantz has provided contact information for those wishing to engage in potential litigation related to this issue, indicating a robust platform for investors to voice their claims and seek redress. As usual, the firm cautions that prior results in cases handled by them do not guarantee similar outcomes for new cases.
In this turbulent financial climate for Altimmune, investors watching closely will want to stay informed about any further updates related to this investigation. The outcome may not only impact the value of their investments but could also set precedents for the treatment of securities fraud in the biotech sector. As always, taking prompt action is crucial for shareholders to protect their financial interests in companies embroiled in legal disputes. Pomerantz has made it clear that investors should be proactive if they wish to join the pending class action.
For more detailed information or to join the class action lawsuit, potential claimants can reach out to attorney Danielle Peyton at Pomerantz via email or phone. This developing situation will likely continue to attract shareholder attention, making appropriate actions essential for affected individuals.
The basis for this inquiry stems from allegations that Altimmune, along with its executive leaders, may have been involved in securities fraud or engaged in other unlawful business practices. Recently, on June 26, 2025, Altimmune released a press statement summarizing the results of the IMPACT Phase 2b trial, which focused on a drug called pemvidutide aimed at treating metabolic dysfunction-associated steatohepatitis (MASH). While the company labeled the results as "positive," an in-depth analysis was less optimistic regarding key endpoints. Specifically, the reported effectiveness of fibrosis improvement was 31.8% and 34.5% for pemvidutide administered at doses of 1.2 mg and 1.8 mg, respectively, contrasted with a 25.9% improvement in the placebo group. Alarmingly, these differences were not found to be statistically significant.
This critical information had an immediate and dramatic impact on Altimmune's stock market performance. Following the press release, shares of the company plummeted, with a staggering drop of $4.10, equating to a 53.18% decline, leading to a closing price of just $3.61 per share on that day. Such a drastic decline raises red flags, prompting Pomerantz to step in on behalf of the investors who might have been misled regarding the efficacy and safety of Altimmune's treatments.
Pomerantz Law Firm, known for its exemplary work in corporate law and class actions, highlights the importance of transparency in the life sciences sector, especially when it comes to claims made about medical treatments. Founded over 85 years ago by Abraham L. Pomerantz, a pioneer in class action lawsuits, the firm prides itself on advocating for shareholders’ rights. It is recognized for recovering substantial damages for those who have faced corporate wrongdoing, and its current investigation into Altimmune exemplifies its ongoing commitment to this mission.
Investors affected by these developments are urged to act swiftly. Pomerantz has provided contact information for those wishing to engage in potential litigation related to this issue, indicating a robust platform for investors to voice their claims and seek redress. As usual, the firm cautions that prior results in cases handled by them do not guarantee similar outcomes for new cases.
In this turbulent financial climate for Altimmune, investors watching closely will want to stay informed about any further updates related to this investigation. The outcome may not only impact the value of their investments but could also set precedents for the treatment of securities fraud in the biotech sector. As always, taking prompt action is crucial for shareholders to protect their financial interests in companies embroiled in legal disputes. Pomerantz has made it clear that investors should be proactive if they wish to join the pending class action.
For more detailed information or to join the class action lawsuit, potential claimants can reach out to attorney Danielle Peyton at Pomerantz via email or phone. This developing situation will likely continue to attract shareholder attention, making appropriate actions essential for affected individuals.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.